Merck KGaA ends lung cancer vaccine trials

FRANKFURT, Sept 12 (Reuters) - German drugmaker Merck KGaA drug stopped all remaining clinical studies of the experimental lung cancer vaccine tecemotide, formerly known as Stimuvax, after renewed attempts to show its effectiveness failed.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.